tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Halozyme Earnings Call Highlights Royalty-Fueled Growth
PremiumCompany AnnouncementsHalozyme Earnings Call Highlights Royalty-Fueled Growth
27d ago
Halozyme: Strong Royalty Momentum and Underappreciated Multi‑Year Earnings Power Support Buy Rating
Premium
Ratings
Halozyme: Strong Royalty Momentum and Underappreciated Multi‑Year Earnings Power Support Buy Rating
28d ago
Halozyme reaffirms FY26 non-GAAP EPS view $7.75-$8.25, consensus $8.18
Premium
The Fly
Halozyme reaffirms FY26 non-GAAP EPS view $7.75-$8.25, consensus $8.18
29d ago
Halozyme raises FY25 revenue view to $1.39B-$1.4B from $1.3B-$1.38B
PremiumThe FlyHalozyme raises FY25 revenue view to $1.39B-$1.4B from $1.3B-$1.38B
2M ago
Leerink views ‘major deal’ on Entyvio as positive for Halozyme
Premium
The Fly
Leerink views ‘major deal’ on Entyvio as positive for Halozyme
2M ago
Halozyme: ENHANZE Platform Partnerships in Immunology and Obesity Drive Underappreciated Royalty Upside and Support Buy Rating
Premium
Ratings
Halozyme: ENHANZE Platform Partnerships in Immunology and Obesity Drive Underappreciated Royalty Upside and Support Buy Rating
2M ago
Skye Bioscience, Halozyme enter collaboration, license agreement
PremiumThe FlySkye Bioscience, Halozyme enter collaboration, license agreement
2M ago
Halozyme, Skye Bioscience announce global collaboration, license agreement
Premium
The Fly
Halozyme, Skye Bioscience announce global collaboration, license agreement
2M ago
Rybrevant FASPRO Approval and ENHANZE Royalties Reset Halozyme’s Long-Term Growth Outlook, Supporting a Buy Rating and $90 Target
Premium
Ratings
Rybrevant FASPRO Approval and ENHANZE Royalties Reset Halozyme’s Long-Term Growth Outlook, Supporting a Buy Rating and $90 Target
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100